BioSpace News Archive

Medikine, Inc., a preclinical-stage biopharmaceutical company developing innovative peptide-based agonists of cytokine receptors relevant to cancer treatment, today announced that it will deliver three poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020),

Indivumed announced today the launch of its new, AI-integrated Advanced Data Analytics Platform which will accelerate drug targets and diagnostics discoveries.

Boston Children’s Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and Deerfield Management Company, a healthcare investment firm, announced a major research collaboration to advance promising therapeutics that will address unsolved medical needs and find cures for disease.

Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday, November 17, 2020, at the Jefferies Virtual London Healthcare Conference.

ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced that it will report its third quarter 2020 financial and operational results on Thursday, November 12, 2020 after the close of the U.S. financial markets.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Eric Bjerkholt as Chief Financial Officer (CFO).

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16 at 4:40 p.m. Eastern Time.

Pascal Biosciences Inc. announced the appointment of Mark van der Horst to the position of Vice President of Corporate Communications.

The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that it is now supplying healthcare providers with CareStart™ COVID-19 Antigen Rapid Point-of-Care (POC) test kits.

- 35 % of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2. 4 % for vehicle (p=0.0001) - - VP-102 was well-tolerated with no reported serious adverse events related to VP-102 - - Approximately 500,000 to 1 million cases of EGW are newly diagnosed per year in the United States - - Based on positive outcome, Verrica will request an End - of - Phase 2 meeting with the FDA -